autologous bone marrow mononuclear cells (National Cerebral and Cardiovascular Center)

This is an investigational autologous cell therapy developed by the National Cerebral and Cardiovascular Center (NCVC) in Japan for the treatment of severe cerebral embolism (embolic stroke). The therapy involves the intravenous administration of a heterogeneous population of mononuclear cells—including mesenchymal stem cells, hematopoietic progenitor cells, and endothelial progenitor cells—harvested from the patient's own bone marrow approximately 7 to 10 days after the stroke event. The biological mechanism is thought to involve neuroprotection, stimulation of neuroregeneration, and enhancement of cerebral blood flow and metabolism. A Phase 1/2a clinical trial (NCT01028794) demonstrated the safety and feasibility of the treatment in patients with severe neurological deficits, showing trends toward improved neurological outcomes.

Other names

BM-MNCsautologous bone marrow-derived mononuclear cells